What Atley Solutions does

Atley Solutions AB is a Swedish private company founded in 2019 and headquartered in Gothenburg, with product development and manufacturing operations in Kristinehamn and an additional office in Åmål. The company develops and sells commercial products and services that enable the manufacture of Astatine-211 (At-211) radiopharmaceuticals for targeted alpha therapy in cancer treatment, serving pharmaceutical and biotech drug developers, contract research organizations, and academic medical centers. Atley positions itself as the only provider of a commercial automated manufacturing system purpose-built for At-211, which has a 7.2-hour half-life and therefore requires local, decentralized production close to the clinic.

The company's core product is the Atley C100, a CE-marked and CB-certified (IEC 61010-1) automated manufacturing module that performs two sequential stages: purification of At-211 from irradiated bismuth targets via a proprietary dry distillation process (achieving >80% non-decay-corrected yield in under 20 minutes), followed by automated radiopharmaceutical synthesis and purification. The C100 is designed for GMP compliance and supports production from non-clinical R&D through commercial scale. It is complemented by Atley Targets (Bi-209 bismuth targets engineered for compatibility with multiple cyclotron models) and by At-211 Radiochemical Services covering feasibility projects, manual radiochemistry development, stability studies, and automation development, with weekly At-211 deliveries from Rigshospitalet Copenhagen supporting customer programs.

The business model combines three revenue streams: one-time enterprise hardware sales of C100 modules sold through direct field sales with multi-year service contracts; recurring, usage-based revenue from Bi-209 targets and consumable kits purchased per manufacturing run; and professional services for radiopharmaceutical development. Pricing is quote-based and not publicly disclosed. The company has raised roughly €5M in equity (June 2025, led by Fåhraeus Startup & Growth), 13.7M SEK in 2023 (led by Chalmers Ventures), and a €990K Eurostars-2 grant in 2021; it is also a partner in the €25.3M Horizon Europe Thera4Care consortium led by GE HealthCare. Named customers and partners include UMC Utrecht and Princess Máxima Center, Perceptive Discovery, Stanford University, Minerva Imaging, NAYA Therapeutics, Telix Pharmaceuticals, Forschungszentrum Jülich, and Rigshospitalet.

Name

Atley Solutions

Legal name

Atley Solutions AB

Website

https://atley.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Atley Solutions AB, founded 2019 in Sweden, provides the Atley C100 automated manufacturing module, Atley Targets consumables, and At-211 radiochemistry services for Astatine-211 radiopharmaceutical production, serving pharmaceutical companies, CROs, and academic medical centers developing targeted alpha cancer therapies.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Manufacturing Equipment

NAICS

Irradiation Apparatus Manufacturing (334517)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)

akta.pro secondary industries

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Nuclear Materials Testing, Assay & Characterization Services (NDA/NDE, radiochemistry, materials analysis) (EUAKAIAL)

Keywords

• Radiopharmaceutical manufacturing
• Astatine-211 production
• Targeted alpha therapy
• Automated radiochemistry systems
• Radiopharmaceutical development services

Headquarters

HQ city

Gothenburg

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Atley C100 Hardware Sales: Sale of Atley C100 automated manufacturing modules to pharmaceutical companies, CROs, and academic institutions. The C100 is the world's first commercial module for At-211 radiopharmaceutical manufacturing. Hardware sales are complemented by ongoing service and support contracts.
2. Disposables and Consumables: Sale of disposable items including Atley Targets (Bi-209 targets) and customized consumable kits for each manufacturing occasion. This creates recurring revenue per manufacturing run, providing volume sales potential given the limited half-life of At-211 (7.2 hours) requiring local production.
3. Radiochemistry Development Services: Service offerings including feasibility projects, manual radiochemistry development, stability studies, and automation development using the Atley C100. These services help pharmaceutical companies generate clinical candidates and prepare them for clinical trials, building the market for hardware products.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Atley Solutions develops and manufactures the Atley C100, the world's first and only commercial automated manufacturing system specifically designed for At-211 radiopharmaceuticals, which purifies astatine-211 from irradiated bismuth targets via dry distillation and performs automated synthesis. The company also sells Atley Targets (Bi-209 targets) as recurring consumables and offers At-211 Radiochemical Services for feasibility, radiochemistry development, stability studies, and automation projects.

Product overview

Atley Solutions provides a portfolio of products and services for At-211 radiopharmaceutical manufacturing. The flagship product is the Atley C100, the world's first and only commercial automated manufacturing system specifically designed for At-211 radiopharmaceuticals, performing both purification and synthesis. This core platform is complemented by Atley Targets (high-quality Bi-209 targets for At-211 production via cyclotron irradiation) and At-211 Radiochemical Services (comprehensive R&D support including feasibility studies, manual radiochemistry development, stability studies, and radiochemistry automation). Together, these offerings enable scalable, GMP-compliant manufacturing of At-211-based targeted alpha therapies for precision oncology.

Differentiator

Problem solved

Functional benefit

Brands

• Atley C100: World's first and only commercial manufacturing system specifically designed for At-211 radiopharmaceuticals. The module purifies At-211 from irradiated targets through dry distillation and performs automated radiopharmaceutical synthesis and purification.
• Atley Targets
• At-211 Radiochemical Services

Products and services

• Atley C100 World's first and only commercial automated manufacturing module specifically designed for At-211 radiopharmaceuticals. Performs two key stages: purification of At-211 from irradiated bismuth targets through dry distillation (>80% purification yield, <20 minutes), followed by automated radiopharmaceutical synthesis and purification. CE marked and CB certified compliant to IEC 61010-1. Sold to pharmaceutical companies, CROs, and academic medical centers.
• Atley Targets High-quality Bi-209 (bismuth-209) targets for accelerator-based manufacturing of astatine-211. Engineered for compatibility with a wide range of accelerator models, with customization available. Each target has unique identification for full traceability. Fully compatible with the Atley C100 for seamless integration into automated manufacturing workflows. Sold as recurring consumables per manufacturing run.
• At-211 Radiochemical Services World-class radiopharmaceutical development services including feasibility projects, manual radiochemistry development, stability studies, and radiochemistry automation using the Atley C100. Includes weekly deliveries of high-activity At-211 from Rigshospitalet in Copenhagen. Helps pharmaceutical companies generate clinical candidates and prepare them for clinical trials, building the market for hardware products.

Quantifiable outcome

• >80% At-211 purification yield (non-decay corrected)
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and flagship.

• Forschungszentrum Jülich (INM-5)coreStrategic or Co-development Partner · 24 February 2026Demonstrated scalable supply chain for At-211 involving shipping irradiated bismuth material to UMC Utrecht for purification using Atley C100. Approximately 2.0 GBq of At-211 produced and shipped successfully. Demonstrates flexibility of Atley C100 platform across different supply models and provides redundancy for At-211 supply supporting clinical trials.
• Stanford University and Telix PharmaceuticalsflagshipStrategic or Co-development Partner · 10 February 2026VINNOVA-funded international collaboration to establish first operational At-211 supply chain in California. Atley contributes manufacturing technology including Atley C100 and Bi-209 targets; Stanford provides cGMP manufacturing capacity and clinical expertise; UC Davis Crocker Nuclear Laboratory produces At-211 through target irradiation. Project runs through 2026 with goal of establishing regional supply infrastructure.
• Perceptive DiscoveryflagshipStrategic or Co-development Partner · 22 January 2026Strategic collaboration for sale of two Atley C100 modules for automated At-211 radiopharmaceutical manufacturing. First installation at Perceptive Discovery's lab in Needham, MA (first-ever at commercial CRO in US) and at partner lab at Queen Mary University of London (first in UK). Long-term partnership spanning equipment, services, and knowledge exchange aimed at establishing pioneering At-211 capabilities globally.
• GE Healthcare and Thera4Care ConsortiumflagshipStrategic or Co-development Partner · 1 October 2024Atley participates in Thera4Care consortium led by GE Healthcare with 29 partners from 14 European countries and US. €25.3 million Horizon Europe funded project aims to expand theranostics in Europe. Atley's activities focus on At-211 supply chain improvement and standardization of At-211 radiopharmaceutical manufacturing.
• Minerva ImagingcoreStrategic or Co-development Partner · 1 January 2023Partnership to foster development of radiopharmaceuticals utilizing At-211. Minerva Imaging hosts Atley C100 installation for on-site production. Collaboration combines Atley's automated production expertise with Minerva's pre-clinical and clinical translation experience to offer resources and infrastructure for bringing At-211 drug products to market.
• Telix Pharmaceuticals (ANMI)coreStrategic or Co-development Partner · 7 June 2021€990K Eurostars-2 research grant for development of novel anti-cancer Targeted Alpha Therapy using At-211. Project scope includes scale-up radiochemistry, preclinical studies, and clinical proof-of-concept support. Combines Telix's targeting agents with Atley's automated production platform.
• UMC Utrecht and Princess Máxima CentercoreStrategic or Co-development PartnerUMC Utrecht uses Atley C100 in routine clinical production and is pioneering the world's first clinical translation of At-211 therapy in pediatrics. Dr. Arthur Braat and Dr. Alex Poot lead four planned Phase I trials including neuroblastoma and pheochromocytoma treatments. The team is building GMP manufacturing capabilities and has received collaboration requests from worldwide institutions.
• NAYA TherapeuticscoreStrategic or Co-development PartnerPartnership to accelerate development and commercialization of NAYA's At-211 radiopharmaceuticals using Atley's manufacturing technology and expertise.
• Rigshospitalet (Copenhagen, Denmark)coreStrategic or Co-development PartnerWeekly deliveries of high-activity At-211 from cyclotron facility at Rigshospitalet ensure reliable and consistent support for radiopharmaceutical development projects. Key supply partner for Atley's services and customer development activities.
• UC Davis Crocker Nuclear LaboratorycoreTechnology or IntegrationProduction partner in California supply chain collaboration; produces At-211 through irradiation of Bi-209 targets at cyclotron facility. Parts of the cyclotron originate from the Berkeley 60-inch Cyclotron used in the discovery of astatine in 1940.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• GE HealthCare: Global leader in radiopharma and cyclotron infrastructure, including PET radiopharma production and TRACERcenter services. Comparable to Atley as a broad incumbent in the radiopharma equipment and isotope production ecosystem, and Atley's Chairman and senior engineer both come from GE. Atley is also a partner via the Thera4Care consortium led by GE HealthCare.
• Siemens Healthineers (PETNET Solutions): Operates one of the largest radiopharma manufacturing networks globally through PETNET Solutions, producing FDG and other PET isotopes. A broad incumbent comparable to Atley in radiopharma manufacturing infrastructure, with the scale and customer reach that Atley aspires to in the At-211 niche.
• Eckert & Ziegler: Specializes in isotope production, radiopharma equipment, and radiochemistry services for diagnostic and therapeutic radiopharmaceuticals. Comparable to Atley as a broad incumbent offering both isotope-related hardware and contract services, with a mature global footprint that could eventually compete in alpha-emitter manufacturing.
• IBA (Ion Beam Applications): World leader in cyclotron and particle accelerator manufacturing for medical and industrial use, including radioisotope production. Comparable to Atley because Atley's Bi-209 targets are designed for compatibility with a wide range of accelerator models, and IBA sits upstream in the same supply chain.
• Novartis (Advanced Accelerator Applications / Pluvicto): Owns Pluvicto (Lu-177 PSMA) and operates the largest commercial radioligand therapy manufacturing footprint through Advanced Accelerator Applications. Comparable to Atley as the dominant commercial benchmark in targeted radiopharmaceuticals, illustrating both the scale of the opportunity and the competitive context for At-211.
• Curium Pharma: One of the world's largest nuclear medicine companies, supplying SPECT, PET, and therapeutic isotopes globally. Comparable to Atley as a vertically integrated radiopharma supplier that could expand into alpha-emitter production infrastructure over time.

Emerging players

• Telix Pharmaceuticals: Commercial-stage radiopharma company developing diagnostic and therapeutic radiopharmaceuticals. Both an Atley partner (joint €990K Eurostars grant, TLX102 At-211 program, California supply chain) and a partial adjacent competitor pursuing At-211 drug assets that depend on Atley manufacturing infrastructure.
• Nuclidium: European startup developing copper-based radiotheranostics with proprietary manufacturing technology. Comparable to Atley as an emerging deep-tech radiopharma platform company, and the Atley Senior Engineer previously served as Head of Engineering at Nuclidium, illustrating direct talent overlap in the space.
• NorthStar Medical Radioisotopes: US-based commercial supplier of medical radioisotopes including therapeutic and diagnostic radionuclides. Comparable to Atley as a focused medical radioisotope production and supply company addressing manufacturing challenges for emerging therapeutic radionuclides.

Others

• Bayer (Xofigo / radioligand pipeline): Commercialized the first alpha-emitting therapeutic radiopharmaceutical (Xofigo, Ra-223) and is investing in next-generation targeted alpha therapies. Comparable to Atley as a broad incumbent that validates the clinical viability of alpha-emitting radiopharmaceuticals and could pursue At-211 assets in the future.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/atley-solutions
• Xx.com/atleysolutions

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atley Solutions